AngioDynamics (ANGO) Aktie Kurs

AngioDynamics Kurs

NASDAQ·LUKKET
10,90
​
Markedet lukket

Omsætningen er vokset med 5,7 % om året de seneste 19 år til 320,17 Mio. USD. Indtjening pr. aktie er vokset med 12,5 % om året de seneste 11 år. AngioDynamicss nettoavance ligger på -11,5 %, ned fra -8,4 % for flere år siden. Analytikernes mediankursmål er 19,50 USD, hvilket er over den aktuelle kurs med 78,9 %. Af 10 analytikere anbefaler 9 køb — den samlede vurdering er Køb.

AngioDynamics aktiekurs

Hent disse data via Eulerpool API

AngioDynamics aktie og aktieanalyse

AngioDynamics Inc er en førende leverandør af medicinske device og løsninger til behandling af vaskulære sygdomme og kræft. Selskabet blev grundlagt i 1988 og har hovedkontor i Latham, New York. Gennem årene har AngioDynamics udviklet sig til et konglomerat gennem flere opkøb og partnerskaber med speciale inden for forskellige områder. De vigtigste forretningsområder er Vascular Access Solutions, Oncology Solutions og Peripheral Vascular Solutions. AngioDynamics fokuserer på at udvikle og fremstille innovative teknologier, der forbedrer den medicinske behandling og fremmer patienternes sundhed. Selskabet udvikler og distribuerer et bredt udvalg af medicinske device og procedurer til behandling af sygdomme som kræft, venøse lidelser og trombose. Inden for forretningsområdet Vascular Access Solutions tilbyder AngioDynamics et bredt sortiment af device til etablering af vaskulær adgang, hvilket er nødvendigt ved behandlingen af alvorlige sygdomme. Dette inkluderer port-systemer og katetre, der faciliterer adgangen til kroppens vaskulære system. AngioDynamics' Oncology Solutions giver målrettede behandlingsmuligheder for kræft, herunder ultralydsstyret radiofrekvensablationssystemer og fusion-biopsisystemer. Udviklingen af innovative diagnostiske og terapeutiske muligheder er et centralt fokus for AngioDynamics. Et flertal af AngioDynamics' produkter hører under forretningsområdet Peripheral Vascular Solutions. Her udvikler selskabet device og procedurer til behandling af perifere vaskulære sygdomme såsom åreknuder eller kronisk venøs insufficiens. Dette omfatter procedurer som laser- og radiofrekvensbehandlinger, der kan udføres minimalt invasivt. AngioDynamics har opnået et fremragende ry inden for medicinalbranchen på grund af sine kvalitetsprodukter, innovative teknologier og det tætte samarbejde med læger og sundhedsfagpersonale. Selskabet lægger stor vægt på at sikre optimal pleje til hver enkelt patient og betjener derfor hospitaler, klinikker og lægepraksiser verden over. Gennem årene er AngioDynamics blevet en førende leverandør af medicinske device og løsninger til behandling af vaskulære sygdomme og kræft. Selskabet har opbygget en bred kundebase globalt og er blevet en vigtig aktør i medicinalbranchen takket være kvaliteten og innovationen i sine produkter.

Hyppigt stillede spørgsmål om AngioDynamics-aktien

AngioDynamics Inc operates as a medical device company, specializing in the design, development, manufacturing, and marketing of medical, surgical, and diagnostic devices used in minimally invasive procedures. The company's business model focuses on providing innovative solutions to healthcare professionals for the treatment of vascular diseases and conditions. AngioDynamics offers a wide range of products, including ablation systems, thrombus management devices, venous access products, and peripheral vascular devices. By delivering high-quality and reliable medical devices, AngioDynamics aims to improve patient outcomes and provide value to healthcare providers.

AngioDynamics Inc is primarily active in the medical device industry.

The main competitors of AngioDynamics Inc in the market include Medtronic Inc, Boston Scientific Corporation, and Johnson & Johnson.

AngioDynamics Inc. is a leading medical technology company specializing in the development and manufacture of innovative medical devices used in minimally invasive procedures. The company was founded in 1988 and is headquartered in Latham, New York. AngioDynamics Inc. has a rich history of delivering cutting-edge solutions in areas such as vascular access, peripheral vascular disease, and oncology. With a commitment to improving patient outcomes, AngioDynamics Inc. has established itself as a trusted provider of advanced medical devices to healthcare professionals worldwide. The company's dedication to research, development, and clinical collaboration ensures continued success in the field of minimally invasive interventions.

AngioDynamics Inc has achieved several significant milestones throughout its existence. One notable accomplishment includes the development and commercialization of innovative medical devices for the treatment of peripheral vascular disease and cancer. The company has also expanded its global presence by successfully introducing its products in various international markets. Furthermore, AngioDynamics Inc has received numerous accolades and recognition for its breakthrough technologies, including the FDA approval of its groundbreaking radiofrequency ablation system. With a steadfast commitment to improving patient outcomes, AngioDynamics Inc continues to make strides in the field of medical technology and remains at the forefront of innovation.

AngioDynamics Inc is primarily present in the United States.

AngioDynamics Inc represents values of innovation, patient focus, and commitment to improving medical treatments. The company's corporate philosophy revolves around developing and delivering breakthrough medical technologies that enhance patient care and improve the quality of life. AngioDynamics is dedicated to providing innovative solutions for minimally invasive, image-guided medical procedures, with a focus on delivering superior outcomes for patients. With a strong emphasis on research and development, AngioDynamics continuously strives to advance medical technologies, ensuring patient safety, and revolutionizing the field of medical interventions.

Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 19,50 USD for AngioDynamics-aktien (median: 19,50 USD), svarende til +78,9 % i forhold til seneste kurs. Konsensus bygger på 10 analytikervurderinger.

10 analytikere vurderer i øjeblikket AngioDynamics-aktien: 9 anbefaler køb, 1 hold og 0 salg.

Omregnet til den aktuelle valutakurs handles AngioDynamics-aktien til 9,74 EUR (10,90 USD).

AngioDynamics-aktien (ANGO) er noteret på 2 børser, herunder: NASDAQ (ANGO), Frankfurt (UG2.F).

AngioDynamics Inc. is a leading company in the field of minimally invasive medicine and offers innovative medical technology solutions for vascular diseases, cancer treatment, and interventional radiology. The company operates globally and distributes its products in over 90 countries. The company operates in three main business areas: Vascular Access, Peripheral Vascular, and Oncology. The Vascular Access area includes products such as port systems, catheters, and accessories used to create long-term vascular access for patients requiring repeated blood draws or infusions. The Peripheral Vascular area includes products such as atherectomy systems, thrombectomy systems, and stent systems used for the treatment of peripheral vascular diseases such as atherosclerosis and thrombosis. Oncology offers a wide range of products and systems for cancer treatment, including catheters and port systems. Another important area of AngioDynamics is interventional radiology. The company offers innovative instruments and systems for the diagnosis and treatment of diseases such as liver tumors and prostate enlargement. Products in this area include microwave-assisted tumor ablation systems, needles, catheters, and accessories. AngioDynamics is also a key player in the field of medical imaging. The company provides systems for navigation and visualization of catheters and instruments used in minimally invasive procedures. These products enable physicians to perform precise and safe procedures and offer patients faster recovery. The business model of AngioDynamics is based on the development and marketing of innovative medical solutions that improve the treatment of vascular diseases, cancer, and other diseases. The company invests in research and development to develop new products and technologies that meet the needs of physicians and patients. Additionally, the company collaborates closely with hospitals and medical facilities to ensure rapid adoption and dissemination of its products. AngioDynamics has a strong and diverse product line that enables the company to serve various markets and customers. The company offers high-quality products and solutions that are valued in medical practice worldwide. With its leadership role in research and development of minimally invasive medicine, AngioDynamics is well positioned to continue growing and maintaining its position as a leading company in the industry. Overall, AngioDynamics' business model is focused on providing innovative medical products and solutions that improve the treatment of vascular diseases, cancer, and other diseases. The company operates in multiple business areas and has a strong presence in the global market. With its extensive product line, leadership role in research and development, and close collaboration with hospitals and medical facilities, AngioDynamics is well positioned to maintain its leading role in the industry in the future.

-omsætningen for AngioDynamics er 320,17 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

-overskuddet for AngioDynamics er -36,74 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for AngioDynamics er i øjeblikket -12,47. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af AngioDynamics-aktien.

Pris-til-salgs-forholdet (P/S) for AngioDynamics er i øjeblikket 1,43. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for AngioDynamics-aktien.

AlleAktien-kvalitetsscore for AngioDynamics er 2/10.

ISIN for AngioDynamics er US03475V1017. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for AngioDynamics er A0B9A5. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for AngioDynamics er ANGO. Tickersymbolet bruges til at handle AngioDynamics-aktier på børsen.

Fair værdiTerminal
10,57 USD
Over-/underværdieringTerminal
Fair værdieret
Sektor
Industri
Sundhedsvæsens Udstyr & Forsyninger
Antal aktier
Medarbeidere
Omsætning pr. medarbejder
506.604,43 USD
Omsætningsvækst Ø5 år
EBIT-vækst Ø5 år
Resultatvækst Ø5 år
Land
Valuta
USD
Børsintroduktion
27. maj 2004
ISIN
US03475V1017
CUSIP
03475V101
SEDOL
B00CR04
Markedsværdi
52-ugers interval
AAQS
2 / 10
PEG-forhold
—
P/E-forhold
P/Ee 2027
-40,16
P/Ee 2028
-116,97
P/Ee 2029
49,55
P/Ee 2030
29,46
P/Ee 2031
25,95
P/S
P/Se
1,36
EV/EBIT
—
K/B-forhold
2,63
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-21,51 %
Sidst opdateret 14. okt. 2026, 21.36

AngioDynamics Peer Group

AngioDynamics Ticker

FRANKFURT · UG2.FNASDAQ · ANGO

AngioDynamics FIGI

ANGO:US · BBG000BB5621ANGO:UA · BBG000BB56P6ANGO:UC · BBG000BB5756ANGO:UN · BBG000BB58F3ANGO:UP · BBG000BB58Z1ANGO:UB · BBG000BB59Y0ANGO:UM · BBG000BB5BV8ANGO:UX · BBG000BB5C37ANGO:UD · BBG000BB5G29ANGO:UW · BBG000BB5J41ANGO:UF · BBG000BB5JJ5ANGO:VY · BBG000BB5KC9